Recombinant clonal stable CHO cell line constitutively expressing full length human CD22 protein (Genbank #NM_001771) and the firefly luciferase. Surface expression of CD22 was confirmed by flow cytometry.
This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.
Background
CD22, also known as Siglec-2, is expressed on the membrane of B-cells. It is reported to act as an inhibitory co-receptor of the B-cell receptor to control the body’s B-cell response. In 2017 the FDA approved inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate targeting CD22, for patients with B-cell acute lymphoblastic leukemia (ALL). Additional therapies targeting CD22 are under evaluation.
References
1. Poe J, et al. CD22 and Siglec-G in B cell function and tolerance. Trends Immunol. 2012 Aug; 33(8):413-420.
2. Dorner T, et al. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. Autoimmunity Reviews. 2015 14:1079-1086.
3. Wei G., et al. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. Journal of Hematology and Oncology. 2017 10:1-13.
Storage/Stability
Store in liquid nitrogen immediately upon receipt.
Growth Media
For best results, it is highly recommended to use these validated and optimized media from BPS Bioscience. Other preparations or formulations of media may result in suboptimal performance.
Growth Medium 3A (BPS Bioscience, #60188): F-12K Medium supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 1 mg/ml G418 and 500 μg/ml of Hygromycin B to ensure recombinant expression.
Shipping Temperature
-80°C
Notes
License Disclosure Visit bpsbioscience.com/license for the label license and other key information about this product.